TICKERNERD
Menu
PVLAPVLAHealthcare · Biotechnology

PVLA Stock Forecast: Palvella Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 14 Oct 2026
$123
−4.61% on the day

The 15 Wall Street analysts covering Palvella Therapeutics, Inc. hold a median 12-month price target of $232 — +89.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 30 of 100 as at 14 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$1.9B
Ticker Nerd rank
30 / 100
Median analyst target
$232
Analysts covering
15
Revenue$0.0
Operating income−$21.4M
Net income−$21.9M
Free cash flow−$12.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−6.1%
1M
−19.2%
YTD
+17.1%
1Y
+66.7%
From 52W high
−22.5%
From 52W low
+74.0%
$70
$158
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PVLA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Palvella Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Oct 2026
30 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
89
Value
78
Volatility
61
Quality
51
Accruals
45
Size
37
Revisions
27
Issuance
11
Growth
8

Momentum (89): The shares have been drifting up relative to others.

Growth (8): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PVLA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PVLA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$100$150$200$250Jan 26Apr 26Jul 26Oct 26PVLAHigh $267Median $232Low $205

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says15 analysts
15 Buy0 Hold0 Sell
Low $205Median $232High $267

The green dot is the last close — the median target sits +89.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
12 Oct 2026HC Wainwright & Co.MaintainsBuy$270 → $246
21 Sept 2026Chardan CapitalMaintainsBuy$240
21 May 2026Chardan CapitalMaintainsBuy—
21 May 2026Chardan CapitalMaintainsBuy$240
21 May 2026Stephens & Co.ReiteratesOverweight—
21 May 2026Stephens & Co.ReiteratesOverweight$220
12 May 2026Stephens & Co.InitiatesOverweight—
31 Mar 2026Chardan CapitalMaintainsBuy—
24 Mar 2026HC Wainwright & Co.MaintainsBuy—
16 Mar 2026Chardan CapitalMaintainsBuy—
25 Feb 2026BTIGMaintainsBuy—
25 Feb 2026MizuhoMaintainsOutperform—
24 Feb 2026Chardan CapitalMaintainsBuy—
24 Feb 2026HC Wainwright & Co.MaintainsBuy—
29 Jan 2026BTIGReiteratesBuy—
16 Jan 2026BTIGReiteratesBuy—
7 Jan 2026MizuhoInitiatesOutperform—
16 Dec 2025Canaccord GenuityMaintainsBuy—
16 Dec 2025Chardan CapitalMaintainsBuy—
16 Dec 2025TD CowenMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PVLA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

PVLA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Oct 2026, Palvella Therapeutics, Inc. returned +66.7% against +17.5% for the S&P 500, dividends included.

PVLA vs S&P 500, last 12 monthsTotal return, rebased to 100
100120140160180200220Jan 26Apr 26Jul 26Oct 26PVLAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

PVLA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Palvella Therapeutics, Inc. (PVLA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
13.7×

Cheaper than 48% of US stocks

Price / sales
—
Price / book
8.5×

Cheaper than 11% of US stocks

EV / EBITDA
−48.4×

Cheaper than 94% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−46.6%

Higher than 22% of US stocks

Return on assets
−22.1%

Higher than 18% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Palvella Therapeutics, Inc. (PVLA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Palvella Therapeutics, Inc. has a market value of $1.9B and an enterprise value of $1.7B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$61.7M.

  • Free cash flow in the twelve months to 30 June 2026: −$36.5M.

  • Shares outstanding: 14.4M.

  • Trailing P/E: 13.7×; forward P/E: −15.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Palvella Therapeutics, Inc. employs 29 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Oct 2026

Data provided by Twelve Data

Peers

PVLA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
PVLAPalvella Therapeutics, Inc.$1.9B
30
VIRVir Biotechnology, Inc.$1.8B
92
SRPTSarepta Therapeutics, Inc.$1.8B
73
BRVEBraveheart Bio, Inc.$1.7B
0
XNCRXencor, Inc.$1.7B
84
ZYMEZymeworks, Inc.$1.8B
58
URGNUroGen Pharma Ltd.$1.8B
83

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Palvella Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PVLA news & analysis

Palvella Therapeutics to Present Phase 3 SELVA and Phase 2 TOIVA Results, Along With New Pediatric Analyses, at 2026 PeDRA Annual Conference

GlobeNewsWire · 15 Oct 2026positive

Palvella Therapeutics said it will present Phase 3 SELVA and Phase 2 TOIVA results, along with new pediatric analyses, at the 2026 PeDRA Annual Conference. The announced SELVA analyses highlight improvements in overall disease severity and a blinded combined score assessing lesion height, vesicle appearance, and leaking or bleeding.

Why it matters — The presentations will provide PVLA watchers with updates on clinical results and pediatric analyses for the company’s programs.

Palvella Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference

GlobeNewsWire · 13 Oct 2026neutral

Palvella Therapeutics said members of its management team will participate in a fireside chat at the Chardan 10th Annual Healthcare Conference on October 20, 2026, at 1:45 p.m. ET. The company said a live webcast will be available on its website.

Why it matters — PVLA watchers can hear from company management during the conference via the webcast.

Palvella Therapeutics: FDA Handholding Makes The Regulatory Story Stronger

Seeking Alpha · 29 Sept 2026positive

Palvella Therapeutics has completed the NDA submission for QTORIN rapamycin for microcystic lymphatic malformations, supported by strong Phase 3 data and the FDA's rolling review process. The FDA awarded a third year of OOPD funding after positive Phase 3 results, with no further efficacy studies required, and the company maintains a robust cash position ahead of a targeted US commercial launch in H1 2027.

Why it matters — For Palvella watchers, the regulatory path has become significantly more predictable, with FDA engagement reducing risk and the company's strong cash position supporting manufacturing and launch efforts toward its first US commercialization.

U.S. Food and Drug Administration Awards Additional Funding for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations

GlobeNewsWire · 28 Sept 2026positive

The U.S. Food and Drug Administration awarded additional funding for QTORIN Rapamycin, a treatment for microcystic lymphatic malformations. The NDA submission was completed following positive Phase 3 SELVA results, with a potential U.S. commercial launch in the first half of 2027 if approved.

Why it matters — This additional FDA funding and completed NDA submission advance the company's lead candidate toward a potential U.S. market launch in the first half of 2027.

Palvella Therapeutics Appoints James R. Treat, M.D.

GlobeNewsWire · 9 Sept 2026positive

Palvella Therapeutics announced the appointment of James R. Treat, M.D., who brings expertise in cutaneous vascular anomalies, including microcystic lymphatic malformations, venous malformations, and angiokeratomas.

Why it matters — A PVLA watcher would care because this appointment adds specialized dermatologic expertise relevant to the company's therapeutic focus areas.

FAQ

Frequently asked questions about PVLA stock

What is the PVLA stock price forecast for 2026-2027?

The 15 Wall Street analysts covering Palvella Therapeutics, Inc. have a median 12-month price target of $232, with estimates ranging from $205 to $267. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PVLA stock a buy right now?

Of the 15 analysts covering Palvella Therapeutics, Inc., 15 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Palvella Therapeutics, Inc. 30 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PVLA?

As at 14 Oct 2026, Palvella Therapeutics, Inc. ranks 30 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (89 of 100).

Will PVLA stock go up?

No one can know that. What the data says: the median 12-month target from 15 analysts implies +89.3% from the last close, and Ticker Nerd's factor model ranks Palvella Therapeutics, Inc. 30 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PVLA stock forecast for 2030?

No analyst covering Palvella Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PVLA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $205 to $267 over the next 12 months.

How has PVLA stock performed over the past year?

Palvella Therapeutics, Inc. returned +66.7% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Palvella Therapeutics, Inc. do?

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for serious, rare skin diseases and vascular malformations with no FDA-approved treatment options.

What is the latest news on PVLA?

The most recent item we track (GlobeNewsWire, 15 Oct 2026): "Palvella Therapeutics to Present Phase 3 SELVA and Phase 2 TOIVA Results, Along With New Pediatric Analyses, at 2026 PeDRA Annual Conference". Palvella Therapeutics said it will present Phase 3 SELVA and Phase 2 TOIVA results, along with new pediatric analyses, at the 2026 PeDRA Annual Conference. The announced SELVA analyses highlight improvements in overall disease severity and a blinded combined score assessing lesion height, vesicle appearance, and leaking or bleeding.

Company

About Palvella Therapeutics, Inc.

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for serious, rare skin diseases and vascular malformations with no FDA-approved treatment options. The company centers its work on dermatology-focused rare disease programs, using its proprietary QTORIN platform to create topical therapies designed for localized delivery in difficult-to-treat conditions. Its current pipeline includes product candidates being studied for microcystic lymphatic malformations, cutaneous venous malformations, and clinically significant angiokeratomas, reflecting a focus on genetically driven and orphan skin disorders. Palvella Therapeutics serves the rare disease and specialty dermatology markets, where targeted medicines can address conditions that are often chronic, burdensome, and underserved by existing therapies. Palvella Therapeutics, Inc. is headquartered in Wayne, Pennsylvania.

CEO Mr. Wesley H. Kaupinen · 29 employees · United States · https://palvellatx.com